Your session is about to expire
← Back to Search
Brexucabtagene Autoleucel for Mantle Cell Lymphoma (ZUMA-2 Trial)
ZUMA-2 Trial Summary
This trial is testing a new treatment for mantle cell lymphoma, a cancer of the blood.
ZUMA-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowZUMA-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ZUMA-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your blood has enough platelets (tiny cells that help with clotting) and the count is at least 75,000 per microliter.My heart functions well, with no fluid around it and normal heart rhythm.I've had up to 5 treatments for MCL, including specific drugs, but no BTK inhibitors.You have at least one area of your body that can be measured to monitor changes during the study.Your oxygen level is more than 92% without any additional oxygen supply.My kidneys are functioning well.
- Group 1: Brexucabtagene autoleucel (KTE-X19)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are currently involved in this research endeavor?
"Affirmative. According to the clinicaltrials.gov website, this clinical trial is currently recruiting participants and has been since April 27th 2021 with its most recent edit being November 14th 2022. The study is aiming to enroll 90 patients at 24 different medical sites."
What has been the precedent of employing Cyclophosphamide in scientific research?
"Since its inception in 1997 at the City of Hope Comprehensive Cancer Center, cyclophosphamide has been studied across 1275 completed clinical trials. Currently, 890 active studies are enrolling patients with a large concentration happening out of Columbus, Ohio."
Is there currently an opportunity for individuals to join this research?
"Indeed, according to clinicaltrials.gov this trial is actively looking for participants since it was initially posted on April 27th 2021 and most recently updated on November 14th 2022. 90 people are needed from 24 different medical centres."
What indications are typically targeted with Cyclophosphamide treatment?
"Cyclophosphamide is regularly prescribed to treat multiple sclerosis, but can also assist with the management of leukemia, myelocytic acute refractory B-cell precursor acute lymphoblastic leukemia and retinoblastoma."
Is Cyclophosphamide permissible under the FDA's regulations?
"Cyclophosphamide has been assessed to have a safety rating of 2 due to existing evidence indicating its security, yet no definitive proof testifying the treatment's effectiveness."
Share this study with friends
Copy Link
Messenger